Activation of macrophage CD8:: Pharmacological studies of TNF and IL-1β production

被引:30
作者
Lin, TJ
Hirji, N
Stenton, GR
Gilchrist, M
Grill, BJ
Schreiber, AD
Befus, AD [1 ]
机构
[1] Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada
[2] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.4049/jimmunol.164.4.1783
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previously, we demonstrated that rat macrophages express CD8 and that Ab to CD8 stimulates NO production. We confirm that CDS is expressed by rat macrophages and extend understanding of its functional significance. Activation of CD8 alpha (OX8 Ab) on alveolar macrophages stimulated mRNA expression for TNF and IL-1 beta and promoted TNF and IL-1 beta secretion. Similarly, OX8 Ab (CD8 alpha) stimulated NR8383 cells to secrete TNF, IL-1 beta, and NO. Activation of CD8 beta (Ab 341) on alveolar macrophages increased mRNA expression for TNF and IL-1 beta and stimulated secretion of TNF, but not IL-1 beta. Interestingly, anti-CD8 Abs did not stimulate IFN-gamma or PGE(2) production, or phagocytosis by macrophages. OX8 (CD8 alpha)-induced TNF and IL-1 beta production by macrophages was blocked by inhibitors of protein tyrosine kinase(s), PP1, and genistein, but not by phosphatidylinositol-3 kinase inhibitor, wortmannin. Moreover, OX8 stimulated protein tyrosine kinase activity in NR8383 cells. Further analysis of kinase dependence using antisense to Syk kinase demonstrated that TNT, but not IL-1 beta, stimulation by CD8 alpha is Syk dependent. By contrast, protein kinase C inhibitor Ro 31-8220 had no effect on OX8-induced TNF production, whereas OX8-induced IL-1 beta production was blocked by Ro 31-8220, Thus, there are distinct signaling mechanisms involved in CD8 alpha (OX8)-induced TNF and IL-1 beta production. In summary, macrophages express CDS molecules that, when activated, stimulate TNF and IL-1 beta expression, probably through mechanisms that include activation of Src and Syk kinases and protein kinase C. These findings identify a previously unknown pathway of macrophage activation likely to be involved in host defense and inflammation.
引用
收藏
页码:1783 / 1792
页数:10
相关论文
共 62 条
[1]  
AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
[2]   Tumour necrosis factor-alpha (TNF-alpha): The good, the bad and potentially very effective [J].
Barbara, JAJ ;
VanOstade, X ;
Lopez, AF .
IMMUNOLOGY AND CELL BIOLOGY, 1996, 74 (05) :434-443
[3]   THE CD4 AND CD8 ANTIGENS ARE COUPLED TO A PROTEIN-TYROSINE KINASE (P56LCK) THAT PHOSPHORYLATES THE CD3 COMPLEX [J].
BARBER, EK ;
DASGUPTA, JD ;
SCHLOSSMAN, SF ;
TREVILLYAN, JM ;
RUDD, CE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) :3277-3281
[4]   LIPOPOLYSACCHARIDE-INDUCED CYTOKINE PRODUCTION IN HUMAN MONOCYTES - ROLE OF TYROSINE PHOSPHORYLATION IN TRANSMEMBRANE SIGNAL-TRANSDUCTION [J].
BEATY, CD ;
FRANKLIN, TL ;
UEHARA, Y ;
WILSON, CB .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (06) :1278-1284
[5]   The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase [J].
Beltman, J ;
McCormick, F ;
Cook, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (43) :27018-27024
[6]  
BOGDAN C, 1992, J BIOL CHEM, V267, P23301
[7]  
Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO
[8]  
2-O
[9]   Phosphoinositide 3-kinase and p72(syk) noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif - Reconstitution with synthetic phosphopeptides [J].
Chacko, GW ;
Brandt, JT ;
Coggeshall, KM ;
Anderson, CL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (18) :10775-10781
[10]   INTERLEUKIN-1 - AN IMPORTANT MEDIATOR OF HOST-RESISTANCE AGAINST PNEUMOCYTIS-CARINII [J].
CHEN, WX ;
HAVELL, EA ;
MOLDAWER, LL ;
MCINTYRE, KW ;
CHIZZONITE, RA ;
HARMSEN, AG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (03) :713-718